Inflammation is associated with voriconazole trough concentrations

Antimicrob Agents Chemother. 2014 Dec;58(12):7098-101. doi: 10.1128/AAC.03820-14. Epub 2014 Sep 15.

Abstract

Voriconazole concentrations display a large variability, which cannot completely be explained by known factors. Inflammation may be a contributing factor, as inflammatory stimuli can change the activities and expression levels of cytochrome P450 isoenzymes. We explored the correlation between inflammation, reflected by C-reactive protein (CRP) concentrations, and voriconazole trough concentrations. A retrospective chart review of patients with at least one steady-state voriconazole trough concentration and a CRP concentration measured on the same day was performed. A total of 128 patients were included. A significantly (P < 0.001) higher voriconazole trough concentration was observed in patients with severe inflammation (6.2 mg/liter; interquartile range [IQR], 3.4 to 8.7 mg/liter; n = 20) than in patients with moderate inflammation (3.4 mg/liter; IQR, 1.6 to 5.4 mg/liter; n = 60) and in patients with no to mild inflammation (1.6 mg/liter; IQR, 0.8 to 3.0 mg/liter; n = 48). The patients in all three groups received similar voriconazole doses based on mg/kg body weight (P = 0.368). Linear regression analyses, both unadjusted and adjusted for covariates of gender, age, dose, route of administration, liver enzymes, and interacting coadministered medications, showed a significant association between voriconazole and CRP concentration (P < 0.001). For every 1-mg/liter increase in the CRP concentration, the voriconazole trough concentration increased by 0.015 mg/liter (unadjusted 95% confidence interval [CI], 0.011 to 0.020 mg/liter; adjusted 95% CI, 0.011 to 0.019 mg/liter). Inflammation, reflected by the C-reactive protein concentration, is associated with voriconazole trough concentrations. Further research is necessary to assess if taking the inflammatory status of a patient into account is helpful in therapeutic drug monitoring of voriconazole to maintain concentrations in the therapeutic window, thereby possibly preventing suboptimal treatment or adverse events.

MeSH terms

  • Adult
  • Age Factors
  • Antifungal Agents / blood
  • Antifungal Agents / pharmacokinetics*
  • Antifungal Agents / pharmacology
  • Aspergillosis / blood
  • Aspergillosis / drug therapy*
  • Aspergillosis / microbiology
  • Aspergillosis / pathology
  • Aspergillus fumigatus / drug effects
  • Aspergillus fumigatus / growth & development
  • C-Reactive Protein / metabolism*
  • Drug Monitoring
  • Female
  • Humans
  • Inflammation / blood
  • Inflammation / drug therapy
  • Inflammation / microbiology
  • Inflammation / pathology
  • Linear Models
  • Male
  • Middle Aged
  • Retrospective Studies
  • Sex Factors
  • Voriconazole / blood
  • Voriconazole / pharmacokinetics*
  • Voriconazole / pharmacology

Substances

  • Antifungal Agents
  • C-Reactive Protein
  • Voriconazole